An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence

Abstract

ObjectiveTo assess the validity of the GLOBOCAN methods for deriving national estimates of cancer incidence.MethodsWe obtained incidence and mortality data from Norway by region, year of diagnosis, cancer site, sex and 5-year age group for the period 1983–2012 from the NORDCAN database. Estimates for the year 2010 were derived using nine different methods from GLOBOCAN. These included the projection of national historical rates, the use of regional proxies and the combination of national mortality data with mortality to incidence ratios or relative survival proportions. We then compared the national estimates with recorded cancer incidence data.FindingsDifferences between the estimates derived using different methods varied by cancer site and sex. Methods based on projections performed better where major changes in recent trends were absent. Methods based on mortality data performed less well for cancers associated with small numbers of deaths and for cancers detectable by screening. In countries with longstanding cancer registries of high quality, regional-based, or trends-based incidence estimates perform reasonably well in comparison with recorded incidence.ConclusionAlthough the performance of the GLOBOCAN methods varies by cancer site and sex in this study, the results emphasize a need for more high-quality population-based cancer registries – either regional or, where practical and feasible, national registries – to describe cancer patterns and trends for planning cancer control priorities.

Cáncer: magnitud del problema en el mundo y en Uruguay, aspectos epidemiológicos

“…En este sentido las estimaciones globales realizadas por la IARC son importantes para comparar regiones o países, pero por las razones señaladas, pueden tener en algunos casos limitaciones importantes (13) . Un complemento más fiable de esta información es aquella proporcionada por la publicación quinquenal de la misma agencia denominada Cancer Incidence in Five Continents, que publica los datos de los registros de base poblacional que satisfacen ciertos criterios de calidad (14) .…”

Synthesis of quinazolindionyl amino acid derivatives as possible antitumour agents

“…[1][2][3] Chemotherapy with cytotoxic drugs is one of the main approaches to dealing with established cancer. 4,5 The main drawbacks of the current chemotherapy of cancer are the severe toxic effects such as emesis and myelosuppression, in addition to the lack of selectivity of the drugs against tumour cells as compared with normal cells.…”

Oncological Scenario in Developing Countries – Little Light at the End of Tunnel

“…Based on GLOBOCAN and International Agency for Research on Cancer (IARC) estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide, this figure is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths by 2030. 1 Globally, the cancer burden is gradually shifting to developing and under-developed world, which currently account for about 57% of new cases and 65% of cancer deaths worldwide. 1,2 However, the oncology scenario in most developing countries is still dismal, plagued by lack of screening, delayed diagnosis, long travel time to cancer hospital, shortage of cancer centres, poor infrastructure, outdated technology, manpower crunches, long waiting lists, lack of accommodation for outstation patients, lack of affordability and apathy of government agencies.…”

“…1 Globally, the cancer burden is gradually shifting to developing and under-developed world, which currently account for about 57% of new cases and 65% of cancer deaths worldwide. 1,2 However, the oncology scenario in most developing countries is still dismal, plagued by lack of screening, delayed diagnosis, long travel time to cancer hospital, shortage of cancer centres, poor infrastructure, outdated technology, manpower crunches, long waiting lists, lack of accommodation for outstation patients, lack of affordability and apathy of government agencies. With regard to India, from an estimated incidence of 1.45 million cases in 2016, the cancer incidence is expected to reach 1.75 million cases in 2020.…”